首页 > 最新文献

ACS Medicinal Chemistry Letters最新文献

英文 中文
Novel PARP7 Inhibitors for Treating Cancer
IF 3.5 3区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2025-03-20 DOI: 10.1021/acsmedchemlett.5c0012710.1021/acsmedchemlett.5c00127
Ram W. Sabnis*, 

Provided herein are novel PARP7 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer and processes for preparing such compounds.

{"title":"Novel PARP7 Inhibitors for Treating Cancer","authors":"Ram W. Sabnis*,&nbsp;","doi":"10.1021/acsmedchemlett.5c0012710.1021/acsmedchemlett.5c00127","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.5c00127https://doi.org/10.1021/acsmedchemlett.5c00127","url":null,"abstract":"<p >Provided herein are novel PARP7 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer and processes for preparing such compounds.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 4","pages":"526–527 526–527"},"PeriodicalIF":3.5,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143809862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhancing the Stability of 211At Radiopharmaceuticals: Insights from Ortho-Substituent Strategies
IF 3.5 3区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2025-03-20 DOI: 10.1021/acsmedchemlett.5c0010210.1021/acsmedchemlett.5c00102
Taoqian Zhao,  and , Steven H. Liang*, 

Astatine-211 (211At) is a promising alpha-emitting radionuclide for targeted alpha therapy (TAT), delivering high linear energy transfer (LET) and a short radiation range, making it ideal for cancer treatment while minimizing damage to surrounding healthy tissue. This viewpoint highlights recent advancements in the development of astatine-211 compounds for TAT, with a focus on the role of neighboring substituents in enhancing in vivo stability. By mitigating deastatination, these structural modifications improve radiopharmaceutical integrity, paving the way for more effective and clinically viable 211At-based radiopharmaceuticals.

{"title":"Enhancing the Stability of 211At Radiopharmaceuticals: Insights from Ortho-Substituent Strategies","authors":"Taoqian Zhao,&nbsp; and ,&nbsp;Steven H. Liang*,&nbsp;","doi":"10.1021/acsmedchemlett.5c0010210.1021/acsmedchemlett.5c00102","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.5c00102https://doi.org/10.1021/acsmedchemlett.5c00102","url":null,"abstract":"<p >Astatine-211 (<sup>211</sup>At) is a promising alpha-emitting radionuclide for targeted alpha therapy (TAT), delivering high linear energy transfer (LET) and a short radiation range, making it ideal for cancer treatment while minimizing damage to surrounding healthy tissue. This viewpoint highlights recent advancements in the development of astatine-211 compounds for TAT, with a focus on the role of neighboring substituents in enhancing in vivo stability. By mitigating deastatination, these structural modifications improve radiopharmaceutical integrity, paving the way for more effective and clinically viable <sup>211</sup>At-based radiopharmaceuticals.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 4","pages":"504–507 504–507"},"PeriodicalIF":3.5,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.acs.org/doi/epdf/10.1021/acsmedchemlett.5c00102","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143809870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
End-to-End Backbone Cyclization Enhances Passive Permeability of bRo5 Oligomeric Depsipeptides with Nonlinear Size Dependence
IF 3.5 3区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2025-03-20 DOI: 10.1021/acsmedchemlett.5c0003710.1021/acsmedchemlett.5c00037
Madelaine P. Thorpe, Corey R. Hopkins and Jeffrey N. Johnston*, 

A majority of drugs are small molecules that satisfy Lipinski’s Rule-of-Five (Ro5), but efforts to target topologically complex biomolecular interactions have reignited interest in nonconforming molecular therapeutics, dubbed “beyond Ro5 (bRo5)”. Broadly useful design principles for bRo5 molecules are few in number, although several studies have highlighted the benefit to bioavailability and proteolytic stability that can result from the introduction of a constraining ring into conformationally mobile peptides. Here we show that a linear oligomeric depsipeptide (OD) template can be leveraged to link size to permeability, while the corresponding cyclic oligomeric depsipeptide (COD) series is used to determine the impact of cyclization as an added conformational constraint. Unexpectedly, certain macrocycle sizes confer a greater benefit to permeability than others.

{"title":"End-to-End Backbone Cyclization Enhances Passive Permeability of bRo5 Oligomeric Depsipeptides with Nonlinear Size Dependence","authors":"Madelaine P. Thorpe,&nbsp;Corey R. Hopkins and Jeffrey N. Johnston*,&nbsp;","doi":"10.1021/acsmedchemlett.5c0003710.1021/acsmedchemlett.5c00037","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.5c00037https://doi.org/10.1021/acsmedchemlett.5c00037","url":null,"abstract":"<p >A majority of drugs are small molecules that satisfy Lipinski’s Rule-of-Five (Ro5), but efforts to target topologically complex biomolecular interactions have reignited interest in nonconforming molecular therapeutics, dubbed “beyond Ro5 (bRo5)”. Broadly useful design principles for bRo5 molecules are few in number, although several studies have highlighted the benefit to bioavailability and proteolytic stability that can result from the introduction of a constraining ring into conformationally mobile peptides. Here we show that a linear oligomeric depsipeptide (OD) template can be leveraged to link size to permeability, while the corresponding cyclic oligomeric depsipeptide (COD) series is used to determine the impact of cyclization as an added conformational constraint. Unexpectedly, certain macrocycle sizes confer a greater benefit to permeability than others.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 4","pages":"638–645 638–645"},"PeriodicalIF":3.5,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.acs.org/doi/epdf/10.1021/acsmedchemlett.5c00037","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143809871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
1,6-Naphthridine Compounds as SMARCA2 Inhibitors for Treating Non-small Cell Lung Cancer
IF 3.5 3区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2025-03-20 DOI: 10.1021/acsmedchemlett.5c0012810.1021/acsmedchemlett.5c00128
Ram W. Sabnis*, 

Provided herein are novel 1,6-naphthridine compounds as SMARCA2 inhibitors, pharmaceutical compositions, use of such compounds in treating non-small cell lung cancer and processes for preparing such compounds.

{"title":"1,6-Naphthridine Compounds as SMARCA2 Inhibitors for Treating Non-small Cell Lung Cancer","authors":"Ram W. Sabnis*,&nbsp;","doi":"10.1021/acsmedchemlett.5c0012810.1021/acsmedchemlett.5c00128","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.5c00128https://doi.org/10.1021/acsmedchemlett.5c00128","url":null,"abstract":"<p >Provided herein are novel 1,6-naphthridine compounds as SMARCA2 inhibitors, pharmaceutical compositions, use of such compounds in treating non-small cell lung cancer and processes for preparing such compounds.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 4","pages":"528–529 528–529"},"PeriodicalIF":3.5,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143809878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Design, Synthesis, and Evaluation of a New Fluorescent Ligand for the M2 Muscarinic Acetylcholine Receptor
IF 3.5 3区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2025-03-20 DOI: 10.1021/acsmedchemlett.4c0059210.1021/acsmedchemlett.4c00592
Renáta Szabó, Dénes Szepesi Kovács, Dóra Judit Kiss, Zeinab Nezafat Yazdi, András Dávid Tóth, Jose Brea, María Isabel Loza, Domokos Meszéna, Lucia Wittner, István Ulbert, Balázs Volk, László Hunyady and György Miklós Keserű*, 

The M2 muscarinic acetylcholine receptor (M2R) is a G protein-coupled receptor involved in regulating cardiovascular functions and mediation of central muscarinic effects, such as movement, temperature control, and antinociceptive responses. Molecular probes targeting this receptor are therefore important in exploring its pathophysiological role at a molecular level. Herein, we report the design, synthesis, and evaluation of a new fluorescent probe for M2R based on an anthranilamide ligand. In radioligand binding experiments, the presented Oregon Green 488-labeled conjugate (33) exhibited high M2R affinity (Ki = 2.4 nM), a moderate preference for the M2R over the M4 receptor, and excellent to pronounced M2R selectivity compared to the M1, M3, and M5 receptors. The utility of the probe was demonstrated in confocal, two-photon, and stimulated emission depletion nanoscopy (STED) imaging to specifically label the receptors in human embryonic kidney (HEK) 293T cells. These properties suggest that our probe may be utilized in advanced microscopy to study the pharmacology of the M2R.

{"title":"Design, Synthesis, and Evaluation of a New Fluorescent Ligand for the M2 Muscarinic Acetylcholine Receptor","authors":"Renáta Szabó,&nbsp;Dénes Szepesi Kovács,&nbsp;Dóra Judit Kiss,&nbsp;Zeinab Nezafat Yazdi,&nbsp;András Dávid Tóth,&nbsp;Jose Brea,&nbsp;María Isabel Loza,&nbsp;Domokos Meszéna,&nbsp;Lucia Wittner,&nbsp;István Ulbert,&nbsp;Balázs Volk,&nbsp;László Hunyady and György Miklós Keserű*,&nbsp;","doi":"10.1021/acsmedchemlett.4c0059210.1021/acsmedchemlett.4c00592","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.4c00592https://doi.org/10.1021/acsmedchemlett.4c00592","url":null,"abstract":"<p >The M<sub>2</sub> muscarinic acetylcholine receptor (M<sub>2</sub>R) is a G protein-coupled receptor involved in regulating cardiovascular functions and mediation of central muscarinic effects, such as movement, temperature control, and antinociceptive responses. Molecular probes targeting this receptor are therefore important in exploring its pathophysiological role at a molecular level. Herein, we report the design, synthesis, and evaluation of a new fluorescent probe for M<sub>2</sub>R based on an anthranilamide ligand. In radioligand binding experiments, the presented Oregon Green 488-labeled conjugate (<b>33</b>) exhibited high M<sub>2</sub>R affinity (<i>K</i><sub>i</sub> = 2.4 nM), a moderate preference for the M<sub>2</sub>R over the M<sub>4</sub> receptor, and excellent to pronounced M<sub>2</sub>R selectivity compared to the M<sub>1</sub>, M<sub>3</sub>, and M<sub>5</sub> receptors. The utility of the probe was demonstrated in confocal, two-photon, and stimulated emission depletion nanoscopy (STED) imaging to specifically label the receptors in human embryonic kidney (HEK) 293T cells. These properties suggest that our probe may be utilized in advanced microscopy to study the pharmacology of the M<sub>2</sub>R.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 4","pages":"552–559 552–559"},"PeriodicalIF":3.5,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.acs.org/doi/epdf/10.1021/acsmedchemlett.4c00592","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143806617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fragment-Based Discovery of Drug-like LRH-1 Agonists
IF 3.5 3区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2025-03-19 DOI: 10.1021/acsmedchemlett.4c0060410.1021/acsmedchemlett.4c00604
Alisa Lang, Niklas Ildefeld, Felix F. Lillich, Astrid Kaiser, Romy Busch, Julian A. Marschner, Ewgenij Proschak, Jan Heering, Manfred Schubert-Zsilavecz and Daniel Merk*, 

The phospholipid sensing transcription factor liver receptor homologue 1 (LRH-1) participates in the transcriptional regulation of metabolic balance and inflammation in liver, pancreas, and other tissues. It is an emerging target for metabolic dysfunction, fatty liver disease, and cancer, but LRH-1 modulators are rare and lack drug-like properties. We discovered new LRH-1 ligands with improved physicochemical features in a fragment-based approach and optimized a venlafaxine-related lead for LRH-1 activation. Despite a strict structure–activity relationship, systematic structural variation resulted in a new LRH-1 agonist scaffold with strong activation efficacy, validated direct and cellular target engagement, and anti-inflammatory and ER-stress-resolving properties in functional cellular settings.

{"title":"Fragment-Based Discovery of Drug-like LRH-1 Agonists","authors":"Alisa Lang,&nbsp;Niklas Ildefeld,&nbsp;Felix F. Lillich,&nbsp;Astrid Kaiser,&nbsp;Romy Busch,&nbsp;Julian A. Marschner,&nbsp;Ewgenij Proschak,&nbsp;Jan Heering,&nbsp;Manfred Schubert-Zsilavecz and Daniel Merk*,&nbsp;","doi":"10.1021/acsmedchemlett.4c0060410.1021/acsmedchemlett.4c00604","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.4c00604https://doi.org/10.1021/acsmedchemlett.4c00604","url":null,"abstract":"<p >The phospholipid sensing transcription factor liver receptor homologue 1 (LRH-1) participates in the transcriptional regulation of metabolic balance and inflammation in liver, pancreas, and other tissues. It is an emerging target for metabolic dysfunction, fatty liver disease, and cancer, but LRH-1 modulators are rare and lack drug-like properties. We discovered new LRH-1 ligands with improved physicochemical features in a fragment-based approach and optimized a venlafaxine-related lead for LRH-1 activation. Despite a strict structure–activity relationship, systematic structural variation resulted in a new LRH-1 agonist scaffold with strong activation efficacy, validated direct and cellular target engagement, and anti-inflammatory and ER-stress-resolving properties in functional cellular settings.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 4","pages":"575–582 575–582"},"PeriodicalIF":3.5,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143806610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Discovery of a Series of Covalent Ligands That Bind to Cys77 of the Von Hippel–Lindau Tumor Suppressor Protein (VHL)
IF 3.5 3区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2025-03-19 DOI: 10.1021/acsmedchemlett.4c0058210.1021/acsmedchemlett.4c00582
Simon C. C. Lucas*, Yong Xu, Sarah Hewitt, Gavin W. Collie, Lucia Fusani, Ganesh Kadamur, Thomas E. Hadfield, Nancy Su, Caroline Truman, Sylvain Demanze, Haie Hao and Christopher Phillips, 

Most ligands for the Von Hippel–Lindau tumor suppressor (VHL) bind at the HIF-1α binding site. Ligands that bind to allosteric sites on VHL could be highly valuable for the field of protein degradation, therefore, a covalent hit identification campaign was run targeting Cys77 on VHL. Hit 2 bound selectively to Cys77 on VHL and did not alkylate the reactive Cys89 on Elongin B. It showed time- and concentration-dependent labeling, with a kinact/KI of 0.30 M–1 s–1, and does not affect binding at the HIF-1α site. This hit ligand was optimized to afford compound 15 which showed improved potency and labeling of VHL. An X-ray structure of a close analogue was determined revealing the compound binding in a shallow groove on the surface of VHL. These are the first small molecules that bind covalently to an allosteric site on VHL and provide a suitable starting point for further optimization.

{"title":"Discovery of a Series of Covalent Ligands That Bind to Cys77 of the Von Hippel–Lindau Tumor Suppressor Protein (VHL)","authors":"Simon C. C. Lucas*,&nbsp;Yong Xu,&nbsp;Sarah Hewitt,&nbsp;Gavin W. Collie,&nbsp;Lucia Fusani,&nbsp;Ganesh Kadamur,&nbsp;Thomas E. Hadfield,&nbsp;Nancy Su,&nbsp;Caroline Truman,&nbsp;Sylvain Demanze,&nbsp;Haie Hao and Christopher Phillips,&nbsp;","doi":"10.1021/acsmedchemlett.4c0058210.1021/acsmedchemlett.4c00582","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.4c00582https://doi.org/10.1021/acsmedchemlett.4c00582","url":null,"abstract":"<p >Most ligands for the Von Hippel–Lindau tumor suppressor (VHL) bind at the HIF-1α binding site. Ligands that bind to allosteric sites on VHL could be highly valuable for the field of protein degradation, therefore, a covalent hit identification campaign was run targeting Cys77 on VHL. Hit <b>2</b> bound selectively to Cys77 on VHL and did not alkylate the reactive Cys89 on Elongin B. It showed time- and concentration-dependent labeling, with a <i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub> of 0.30 M<sup>–1</sup> s<sup>–1</sup>, and does not affect binding at the HIF-1α site. This hit ligand was optimized to afford compound <b>15</b> which showed improved potency and labeling of VHL. An X-ray structure of a close analogue was determined revealing the compound binding in a shallow groove on the surface of VHL. These are the first small molecules that bind covalently to an allosteric site on VHL and provide a suitable starting point for further optimization.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 4","pages":"693–699 693–699"},"PeriodicalIF":3.5,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143806612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unveiling Reality: Psychedelics, Neural Filtering, and the Future of Psychiatric Medicine 揭开现实的面纱迷幻药、神经过滤和精神医学的未来
IF 3.5 3区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2025-03-19 DOI: 10.1021/acsmedchemlett.5c0010310.1021/acsmedchemlett.5c00103
Robert B. Kargbo*, 

Psychedelics and AI modulate cognitive frameworks, disrupt rigid thought patterns, and enhance neuroplasticity, offering therapeutic potential for depression, PTSD, and addiction. Relaxing neural filters reveal altered states of consciousness, challenging perceptions of reality. This Viewpoint explores their neurobiological mechanisms and AI’s role in augmenting psychiatric treatments.

{"title":"Unveiling Reality: Psychedelics, Neural Filtering, and the Future of Psychiatric Medicine","authors":"Robert B. Kargbo*,&nbsp;","doi":"10.1021/acsmedchemlett.5c0010310.1021/acsmedchemlett.5c00103","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.5c00103https://doi.org/10.1021/acsmedchemlett.5c00103","url":null,"abstract":"<p >Psychedelics and AI modulate cognitive frameworks, disrupt rigid thought patterns, and enhance neuroplasticity, offering therapeutic potential for depression, PTSD, and addiction. Relaxing neural filters reveal altered states of consciousness, challenging perceptions of reality. This Viewpoint explores their neurobiological mechanisms and AI’s role in augmenting psychiatric treatments.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 4","pages":"500–503 500–503"},"PeriodicalIF":3.5,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143806611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel 6-Aryl isoindolin-1-one Derivatives as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 2
IF 3.5 3区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2025-03-19 DOI: 10.1021/acsmedchemlett.5c0010710.1021/acsmedchemlett.5c00107
Yinlong Li,  and , Steven H. Liang*, 

This highlight describes a series of novel 6-aryl isoindolin-1-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor 2 (mGluR2). The chemical synthesis, selectivity over mGluR3, and pharmaceutical compositions of those compounds are disclosed.

{"title":"Novel 6-Aryl isoindolin-1-one Derivatives as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 2","authors":"Yinlong Li,&nbsp; and ,&nbsp;Steven H. Liang*,&nbsp;","doi":"10.1021/acsmedchemlett.5c0010710.1021/acsmedchemlett.5c00107","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.5c00107https://doi.org/10.1021/acsmedchemlett.5c00107","url":null,"abstract":"<p >This highlight describes a series of novel 6-aryl isoindolin-1-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor 2 (mGluR<sub>2</sub>). The chemical synthesis, selectivity over mGluR<sub>3</sub>, and pharmaceutical compositions of those compounds are disclosed.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 4","pages":"510–511 510–511"},"PeriodicalIF":3.5,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143806609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Linker-Determined Folding and Hydrophobic Interactions Explain a Major Difference in PROTAC Cell Permeability
IF 3.5 3区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2025-03-17 DOI: 10.1021/acsmedchemlett.5c0006810.1021/acsmedchemlett.5c00068
Vasanthanathan Poongavanam*, Stefan Peintner, Yordanos Abeje, Florian Kölling, Daniel Meibom, Mate Erdelyi and Jan Kihlberg*, 

The ability to adopt folded conformations that have a low solvent-accessible 3D polar surface area has been found to be important for PROTACs to display a high passive cell permeability. We have studied two VHL PROTACs that differ only by the replacement of two methylene groups in the linker by oxygen atoms but that displayed vast differences in their cell permeability. MD simulations and NMR spectroscopy revealed an unexpected, environment-dependent conformational behavior for the low-permeability PROTAC that has an alkyl linker. Hydrophobic interactions enforced extended and polar conformations for this PROTAC in nonpolar media, explaining its low cell permeability. In water, hydrophobic collapse around the linker led to folded and less polar conformations. In contrast, the highly permeable PROTAC having a PEG linker adopted conformations of similar shapes and polarities in polar and nonpolar environments.

{"title":"Linker-Determined Folding and Hydrophobic Interactions Explain a Major Difference in PROTAC Cell Permeability","authors":"Vasanthanathan Poongavanam*,&nbsp;Stefan Peintner,&nbsp;Yordanos Abeje,&nbsp;Florian Kölling,&nbsp;Daniel Meibom,&nbsp;Mate Erdelyi and Jan Kihlberg*,&nbsp;","doi":"10.1021/acsmedchemlett.5c0006810.1021/acsmedchemlett.5c00068","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.5c00068https://doi.org/10.1021/acsmedchemlett.5c00068","url":null,"abstract":"<p >The ability to adopt folded conformations that have a low solvent-accessible 3D polar surface area has been found to be important for PROTACs to display a high passive cell permeability. We have studied two VHL PROTACs that differ only by the replacement of two methylene groups in the linker by oxygen atoms but that displayed vast differences in their cell permeability. MD simulations and NMR spectroscopy revealed an unexpected, environment-dependent conformational behavior for the low-permeability PROTAC that has an alkyl linker. Hydrophobic interactions enforced extended and polar conformations for this PROTAC in nonpolar media, explaining its low cell permeability. In water, hydrophobic collapse around the linker led to folded and less polar conformations. In contrast, the highly permeable PROTAC having a PEG linker adopted conformations of similar shapes and polarities in polar and nonpolar environments.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 4","pages":"681–687 681–687"},"PeriodicalIF":3.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.acs.org/doi/epdf/10.1021/acsmedchemlett.5c00068","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143806578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
ACS Medicinal Chemistry Letters
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1